MKP-6 Activators
MKP-6 Activators comprise a diverse range of chemical compounds that indirectly stimulate the functional activity of MKP-6 by modulating various signaling pathways in which this dual-specificity phosphatase is implicated. Forskolin, through the elevation of intracellular cAMP levels, can indirectly enhance the activity of MKP-6 by activating protein kinase A (PKA), which may phosphorylate substrates including transcription factors that upregulate MKP-6 expression. Similarly, the inhibition of protein phosphatases 1 and 2A by Okadaic Acid results in a compensatory increase in phosphorylated substrates, amplifying the demand for MKP-6's dephosphorylation activity. The competitive inhibition of tyrosine phosphatases by Sodium Orthovanadate can indirectly enhance MKP-6 activity by favoring its action on shared substrates. Bisindolylmaleimide I, as a protein kinase C inhibitor, may indirectly necessitate increased MKP-6 activity to maintain cellular homeostasis in response to altered signaling dynamics.
Further, the MEK inhibitors PD98059 and U0126 may result in upregulation of MKP-6 to counterbalance the diminished ERK phosphorylation, illustrating the adaptive response of cellular signaling networks. LY294002, by inhibiting PI3K, reduces AKT phosphorylation, which could similarly enhance MKP-6's role in MAPK pathway modulation. The intracellular calcium chelator BAPTA-AM and the p38 MAP kinase inhibitor SB203580 may indirectly influence MKP-6 activity by altering the calcium signaling and p38 MAPK signaling, respectively, thereby increasing the requirement for MKP-6-mediated regulation. Anisomycin, by activating JNK, and Sanguinarine, by inhibiting NF-kB, can also contribute to the enhancement of MKP-6 activity by inducing cellular states that demand its phosphatase activity. Collectively, these MKP-6 Activators, by targeting distinct signaling mechanisms, act to potentiate the functional role of MKP-6 in cellular signaling without directly increasing its expression or requiring its direct activation.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Anisomycin is a protein synthesis inhibitor that activates MAPK signaling pathways like JNK and p38 indirectly. Prolonged activation of these pathways could lead to feedback activation of MKP-6 to restore cellular homeostasis by deactivating these MAP kinases. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAP kinase. Its inhibition of p38 can lead to a compensatory upregulation of MKP-6 activity to balance the cellular levels of active p38. | ||||||
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Forskolin activates adenylate cyclase, leading to increased cAMP levels and activation of PKA. PKA can phosphorylate substrates that may stabilize MKP-6, enhancing its activity towards MAP kinases. | ||||||
Dexamethasone | 50-02-2 | sc-29059 sc-29059B sc-29059A | 100 mg 1 g 5 g | $91.00 $139.00 $374.00 | 36 | |
Dexamethasone is a glucocorticoid that can induce MKP-1 expression. Although it is not specific for MKP-6, it may enhance MKP-6 activity indirectly by altering the overall MAP kinase phosphatase activity in cells. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 (PGE2) activates cAMP/PKA signaling. PKA activation can lead to phosphorylation events that stabilize MKP-6, thus enhancing its activity. | ||||||
Sanguinarium | 2447-54-3 | sc-473396 | 10 mg | $220.00 | ||
Sanguinarine can inhibit NF-κB, which is involved in inflammatory responses. Reduced inflammatory signaling could potentially enhance MKP-6 activity by decreasing the need for active p38 and JNK, which MKP-6 deactivates. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is another MEK inhibitor that could theoretically upregulate MKP-6 activity through similar mechanisms as U0126, emphasizing a feedback loop that enhances MKP-6's phosphatase activity. | ||||||
Roscovitine | 186692-46-6 | sc-24002 sc-24002A | 1 mg 5 mg | $94.00 $265.00 | 42 | |
Roscovitine is a cyclin-dependent kinase inhibitor. By altering the cell cycle, it may increase MKP-6 activity as part of cellular stress response mechanisms. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that may lead to enhanced MKP-6 activity by affecting AKT signaling and subsequently modulating feedback loops in MAPK signaling. | ||||||
Stat3 Inhibitor VI, S3I-201 | 501919-59-1 | sc-204304 | 10 mg | $151.00 | 104 | |
S3I-201 inhibits STAT3 signaling. By reducing STAT3 activity, it could potentially enhance MKP-6 activity as STAT3 can influence various cellular stress response pathways including MAP kinase signaling. | ||||||